Carlos Vaca, MD
Critical Care Medicine · Miami, FLNPI 1154437028
Payments from drug & device makers
Across 338 payments — averaging $8740.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$1.5M
- Hikma Pharmaceuticals USA$773K
- Cipla USA Inc.$599K
- AstraZeneca$40K
- Sanofi US Services Inc.$17K
- GSK$12K
- plus $24K from 18 others
Across 1 payment — averaging $668.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$668
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 14 | $1,488,945 |
| Hikma Pharmaceuticals USA | 8 | $772,821 |
| Cipla USA Inc. | 120 | $599,038 |
| AstraZeneca | 34 | $40,370 |
| Sanofi US Services Inc. | 1 | $16,856 |
| GSK | 48 | $11,993 |
| Novartis | 2 | $9,543 |
| Pfizer | 21 | $9,000 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $2,000 |
| Shire North American Group Inc | 1 | $1,000 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 43 | $770 |
| Shionogi Inc | 1 | $408 |
| Novo Nordisk | 3 | $245 |
| Amarin Pharma, Inc. | 11 | $205 |
| Sanofi-aventis U.S. LLC | 10 | $185 |
| Baxter Healthcare | 1 | $177 |
| Welch Allyn | 1 | $177 |
| Lilly USA, LLC | 3 | $138 |
| Biotronik NRO, Inc. | 1 | $84 |
| AbbVie(2 entities) | 5 | $78 |
| Johnson & Johnson | 4 | $67 |
| Dexcom, Inc. | 2 | $29 |
| Boehringer Ingelheim | 1 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $17 |
How this compares
$2,954,169 in reported general payments places this provider in the 95th percentile of 618 critical care medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other critical care medicine in Miami
- Ahmad AswadMiami$6.6M
- Michael CamposMiami$422K
- Alexandre AbreuMiami$179K
- Alexander FortMiami$102K
- Oveimar de la CruzMiami$89K
- Brian GarnetMiami$62K
- Daniel KettMiami$49K
- Raul FernandezMiami$20K
- Jeffrey LevyHollywood$19M
- George DuvallVero Beach$6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.